The New Zealand Commerce Commission has granted clearance for Mylan and Upjohn (a wholly owned subsidiary of Pfizer) to merge their global pharmaceutical businesses. The clearance is subject to a divestment of certain assets.
In New Zealand, both parties compete to supply off-patent prescription medicines. This includes competing to win contracts to supply medicines that are subsidised by the Pharmaceutical Management Agency (PHARMAC) (the public market) and competing to supply unsubsidised medicines outside the PHARMAC process (the private market).
The merging parties offered to divest these products from Upjohn to enable another firm to compete in those markets.
“Subject to the divestment being undertaken, the Commission is satisfied that the proposed merger is unlikely to substantially lessen competition in any New Zealand market,” Commission Chair Anna Rawlings said.
Full Content: Commerce Commission New Zealand
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI